IN2012DN00456A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00456A
IN2012DN00456A IN456DEN2012A IN2012DN00456A IN 2012DN00456 A IN2012DN00456 A IN 2012DN00456A IN 456DEN2012 A IN456DEN2012 A IN 456DEN2012A IN 2012DN00456 A IN2012DN00456 A IN 2012DN00456A
Authority
IN
India
Prior art keywords
therapeutic
research
rapid
systems
animal protein
Prior art date
Application number
Inventor
L Ton Jennifer
A Patel Hemant
C Bates Ronald
M Ahmad Wajdie
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42537891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00456(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2012DN00456A publication Critical patent/IN2012DN00456A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
IN456DEN2012 2009-07-13 2010-07-12 IN2012DN00456A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/502,181 US8129139B2 (en) 2009-07-13 2009-07-13 Process for obtaining botulinum neurotoxin
PCT/US2010/041745 WO2011008713A1 (en) 2009-07-13 2010-07-12 Process and system for obtaining botulinum neurotoxin

Publications (1)

Publication Number Publication Date
IN2012DN00456A true IN2012DN00456A (en) 2015-05-15

Family

ID=42537891

Family Applications (1)

Application Number Title Priority Date Filing Date
IN456DEN2012 IN2012DN00456A (en) 2009-07-13 2010-07-12

Country Status (18)

Country Link
US (19) US8129139B2 (en)
EP (6) EP3252070B1 (en)
JP (6) JP5887268B2 (en)
KR (5) KR101784532B1 (en)
CN (2) CN102482332B (en)
BR (1) BR112012000784A2 (en)
CA (1) CA2767760C (en)
CY (2) CY1119519T1 (en)
DK (2) DK3252070T3 (en)
ES (2) ES2770031T3 (en)
HU (2) HUE033888T2 (en)
IN (1) IN2012DN00456A (en)
MX (4) MX340718B (en)
PL (2) PL3252070T3 (en)
PT (2) PT3252070T (en)
RU (1) RU2561459C2 (en)
SI (2) SI3252070T1 (en)
WO (1) WO2011008713A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7354740B2 (en) 2003-09-25 2008-04-08 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
EP2490986B2 (en) 2009-10-21 2024-04-24 Revance Therapeutics, Inc. Methods and systems for purifying non-complexed botulinum neurotoxin
KR20110046178A (en) * 2009-10-28 2011-05-04 엘지전자 주식회사 Mobile terminal
KR101134146B1 (en) * 2010-05-31 2012-04-19 메덱스젠 주식회사 A method of isolating a non-diffusible and local-paralyzing botulinum toxin subfraction from conventional toxin preparations for clinical use
US9605887B2 (en) 2011-07-29 2017-03-28 Hdt Expeditionary Systems, Inc. Transportable packaged ice supply system for high temperature environments
GB201113544D0 (en) * 2011-08-05 2011-09-21 Fujifilm Diosynth Biotechnologies Uk Ltd Purification process
WO2014197837A1 (en) * 2013-06-06 2014-12-11 University Of Florida Research Foundation, Inc. Materials and methods for producing a biological toxin
BR112016001730B1 (en) * 2013-07-30 2023-04-11 Merz Pharma Gmbh & Co. Kgaa PROCESS FOR THE PREPARATION OF A HIGHLY PURE NEUROTOXIC COMPONENT OF A CLOSTRIDIUM BOTULINUM TOXIN, PHARMACEUTICAL COMPOSITION AND USE OF A HIGHLY PURE NEUROTOXIC COMPONENT OF A CLOSTRIDIUM BOTULINUM TOXIN
KR101339349B1 (en) * 2013-08-02 2013-12-09 주식회사 대웅 Methods for preparing botulinum toxin
AU2014350370B2 (en) * 2013-11-15 2017-04-13 Novartis Ag Removal of residual cell culture impurities
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
KR101729251B1 (en) * 2015-04-28 2017-04-21 주식회사 대웅 Medium Composition for Preparing Botulinum Toxin
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
KR101775682B1 (en) * 2015-11-30 2017-09-06 주식회사 대웅 Methods for Preparing Botulinum Toxin
WO2017161345A1 (en) 2016-03-18 2017-09-21 Biomadison, Inc. Improved cell based assay
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized Clostridium toxin preparations without protein
KR102463881B1 (en) * 2016-10-04 2022-11-07 (주)메디톡스 Method for isolating botulinum toxin from a solution containing botulinum toxin
WO2018175688A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxins for use in therapy
WO2018200991A1 (en) * 2017-04-28 2018-11-01 Bonti, Inc. Botulinum neurotoxins production methods
US20210145955A1 (en) * 2017-06-26 2021-05-20 Bonti, Inc. Clostridial neurotoxin formulations and use
KR102140531B1 (en) * 2018-08-07 2020-08-04 (주)휴온스 The processing method of Gly-Tβ4
US11926853B2 (en) 2018-12-21 2024-03-12 The Research Foundation For Microbial Diseases Of Osaka University Botulinum toxin producing method
KR102197224B1 (en) 2019-03-29 2020-12-31 (주)제테마 A Composition for Culturing Bacteria
KR102209159B1 (en) * 2019-03-29 2021-01-29 (주)제테마 A Method for Producing a Toxin
KR102516203B1 (en) * 2019-04-15 2023-03-30 (주)제테마 Method for preparing Botulinum Toxin
KR102516204B1 (en) * 2019-04-15 2023-03-30 (주)제테마 A Purification Method of Botulinum Toxin
US10851363B1 (en) * 2019-05-22 2020-12-01 Boke Zhang Multilayer nano-cell containing biomolecules
KR102287437B1 (en) * 2019-08-14 2021-08-09 주식회사 프로톡스 Method for preparing botulinum toxin
TW202136286A (en) * 2019-12-20 2021-10-01 瑞士商葛德瑪控股公司 Method of purifying botulinum toxin
TWI854077B (en) * 2019-12-20 2024-09-01 瑞士商葛德瑪控股公司 Method of producing botulinum toxin
CN114958887B (en) * 2021-02-26 2024-10-25 重庆誉颜制药有限公司 Preparation method of modified toxin polypeptide
KR20230146049A (en) * 2021-02-26 2023-10-18 충칭 클라루비스 파마슈티컬 컴퍼니 리미티드 Cell lysis buffer separation equipment, systems and uses thereof for producing polypeptides
KR102724651B1 (en) * 2021-07-08 2024-11-01 주식회사 파마리서치바이오 A method for purifying clostridium botulinum neurotoxin with reduced non-toxic proteins
KR102427362B1 (en) * 2021-11-11 2022-08-01 (주)이니바이오 Drying system for Botulinum toxin formulation
KR102850152B1 (en) * 2022-07-27 2025-08-25 (주)이니바이오 Drying apparatus under reduced pressure and drying method therefor
EP4615489A1 (en) 2022-11-07 2025-09-17 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin
CH720444A2 (en) 2023-01-20 2024-07-31 Abbvie Inc CLOSTRIDIUM BOTULINUM SEROTYPE A NEUROTOXIN (BONT/A) SEQUENCE VARIANTS
CH720447A2 (en) * 2023-01-20 2024-07-31 Abbvie Inc COMPOSITIONS OF CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A
WO2025111258A1 (en) * 2023-11-20 2025-05-30 Abbvie Inc. Clostridium botulinum neurotoxin serotype a compositions and improved filtration processes
DE102025101336A1 (en) 2024-01-19 2025-07-24 Abbvie Inc. COMPOSITIONS OF CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A AND IMPROVED DRYING PROCESSES

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401683A (en) 1981-07-06 1983-08-30 Fmc Corporation Carbohydrate food products resistant to Clostridium botulinum and the formation of enterotoxin
WO1994000481A1 (en) 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
TW257792B (en) * 1992-10-01 1995-09-21 Lilly Co Eli
WO1994009155A1 (en) 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
US5314822A (en) 1992-10-15 1994-05-24 Merck & Co., Inc. Method of clonal growth of Streptococcus pneumoniae
US5962637A (en) 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
WO1996005222A1 (en) 1994-08-08 1996-02-22 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
ES2198484T3 (en) 1995-06-06 2004-02-01 L. Bruce Pearce COMPOSITIONS AND IMPROVED PROCEDURES FOR CHEMICALDERVATION USING NEUROTOXINS.
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
EP1849860B1 (en) 1997-05-28 2010-11-17 Novartis Vaccines and Diagnostics S.r.l. Process for preparing an immunogenic factor of Corynebacterium diphtheriae using a culture medium with yeast extract as aminoacid source and no protein complexes of animal origin
JP4055248B2 (en) 1998-05-25 2008-03-05 味の素株式会社 Purified human activin and method for producing the same
GB9902000D0 (en) * 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
DE19925739A1 (en) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutic with a botulinum neurotoxin
US6558926B1 (en) 1999-07-16 2003-05-06 Massachusetts Institute Of Technology Method for production of tetanus toxin using media substantially free of animal products
AU1571801A (en) 1999-11-12 2001-05-30 Eli Lilly And Company Improved fermentation process
AU1486801A (en) 1999-11-15 2001-05-30 Curagen Corporation Novel growth factor polypeptides and nucleic acids encoding same
DE10004024A1 (en) 2000-01-31 2001-08-02 Guenther Bebenroth Circuit arrangement for operating light-emitting diodes
JP2003522154A (en) 2000-02-08 2003-07-22 アラーガン、インコーポレイテッド Botulinum toxin pharmaceutical composition
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
AU2001272058A1 (en) 2000-02-10 2001-08-20 Magna Intertional Inc. Vehicle tailgate with storage capacity
JP2003009897A (en) 2001-07-03 2003-01-14 Keiji Oguma Method for separating and purifying botulinus toxin
ES2305272T3 (en) 2001-08-14 2008-11-01 Statens Serum Institut PROCESS OF PURIFICATION AT LARGE SCALE OF GLOBULINA GC, PRODUCT OBTAINED BY THE SAME AND ITS USE IN MEDICINE.
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
KR20030060150A (en) 2002-01-07 2003-07-16 (주)메디톡스 Method for purifying clostridium botulinum a type toxin
RU2230325C2 (en) * 2002-08-15 2004-06-10 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Method for preparing purified preparation of botulinic toxin type a
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US20040235139A1 (en) 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
CA2472611C (en) * 2003-07-02 2009-09-15 Illinois Tool Works Inc. Multiple retainer bridge
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7452697B2 (en) 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
US7160699B2 (en) 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7354740B2 (en) 2003-09-25 2008-04-08 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
WO2005072433A2 (en) 2004-01-26 2005-08-11 The Board Of Trustees Of The Leland Stanford Junior University Toxin induced sympathectomy
DK1718756T3 (en) 2004-02-24 2012-02-27 Allergan Inc Botulinumtoksinscreeningassays
KR100852824B1 (en) 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 Therapeutic composition comprising botulinum neurotoxin
US20060069562A1 (en) 2004-09-10 2006-03-30 Adams Marilyn J Word categories
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
US20070258992A1 (en) 2004-10-06 2007-11-08 Atassi M Zouhair Determining and Reducing Immunoresistance to Botulinum Toxin Therapy Using Botulinum Toxin a Peptides
US20070277577A1 (en) 2004-10-29 2007-12-06 Allen Clyde G Sheet metal brake and hinge mechanism therefor
JP2008525381A (en) 2004-12-23 2008-07-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Reduction of the amount of protein contaminants in a composition comprising a vitamin K-dependent protein of interest
ATE552500T1 (en) 2005-04-05 2012-04-15 Allergan Inc LIPOPHILIC, DYE-BASED FRET ASSAYS FOR CLOSTRIDIAL TOXINACTIVITY
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US7744904B1 (en) 2005-09-26 2010-06-29 B.B. Scientific L.L.C. Stabilization of Clostridium botulinum neurotoxin complex
NZ568216A (en) 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US8198034B2 (en) 2008-03-14 2012-06-12 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
KR20090120222A (en) 2008-05-19 2009-11-24 (주)메디톡스 Method for producing Clostridium botulinum toxin using a plant-derived component-containing medium and a flexible closed container
WO2010105236A1 (en) 2009-03-13 2010-09-16 Allergan, Inc. Immuno-based retargeted endopeptidase activity assays
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
EP2490986B2 (en) 2009-10-21 2024-04-24 Revance Therapeutics, Inc. Methods and systems for purifying non-complexed botulinum neurotoxin
NL2010545C2 (en) 2013-03-28 2014-09-30 Ihc Holland Ie Bv Skidding system for an offshore installation or vessel.
KR101339349B1 (en) 2013-08-02 2013-12-09 주식회사 대웅 Methods for preparing botulinum toxin
US9889608B2 (en) 2014-11-10 2018-02-13 International Business Machines Corporation Matching the scale of independent objects or intelligently scaling objects when 3D printing
KR101723167B1 (en) 2015-04-28 2017-04-05 주식회사 대웅 Medium Composition for Preparing Botulinum Toxin
KR101775682B1 (en) 2015-11-30 2017-09-06 주식회사 대웅 Methods for Preparing Botulinum Toxin
KR102463881B1 (en) 2016-10-04 2022-11-07 (주)메디톡스 Method for isolating botulinum toxin from a solution containing botulinum toxin

Also Published As

Publication number Publication date
DK2454275T3 (en) 2017-10-23
PT2454275T (en) 2017-10-23
US10465178B2 (en) 2019-11-05
MX2012000615A (en) 2012-03-26
DK3252070T3 (en) 2020-01-20
MX375629B (en) 2025-03-06
US11530400B2 (en) 2022-12-20
US20220228136A1 (en) 2022-07-21
US8324349B2 (en) 2012-12-04
CN102482332A (en) 2012-05-30
JP5887268B2 (en) 2016-03-16
BR112012000784A2 (en) 2020-08-11
CY1119519T1 (en) 2018-03-07
EP3640259A1 (en) 2020-04-22
US9206409B2 (en) 2015-12-08
KR20150085140A (en) 2015-07-22
US8927229B2 (en) 2015-01-06
EP2454275A1 (en) 2012-05-23
US20230021648A1 (en) 2023-01-26
US20220251532A1 (en) 2022-08-11
US20110008843A1 (en) 2011-01-13
CN102482332B (en) 2016-08-03
EP4699614A2 (en) 2026-02-25
PL2454275T3 (en) 2017-12-29
JP2012532932A (en) 2012-12-20
KR102344985B1 (en) 2021-12-31
US11326155B2 (en) 2022-05-10
US11124786B2 (en) 2021-09-21
EP2454275B1 (en) 2017-07-12
US20230123158A1 (en) 2023-04-20
US20210292727A1 (en) 2021-09-23
US20120108792A1 (en) 2012-05-03
US20220033796A1 (en) 2022-02-03
JP2024111147A (en) 2024-08-16
JP6356651B2 (en) 2018-07-11
RU2561459C2 (en) 2015-08-27
EP4699614A3 (en) 2026-05-13
PL3252070T3 (en) 2020-04-30
HUE047362T2 (en) 2020-04-28
US20120245324A1 (en) 2012-09-27
KR20170019489A (en) 2017-02-21
US12241098B2 (en) 2025-03-04
KR101784532B1 (en) 2017-10-11
SI2454275T1 (en) 2017-12-29
US20170327811A1 (en) 2017-11-16
US20220145279A1 (en) 2022-05-12
PT3252070T (en) 2020-01-14
JP2020078306A (en) 2020-05-28
CY1122567T1 (en) 2021-01-27
US11518986B2 (en) 2022-12-06
MX340718B (en) 2016-07-22
US20120156756A1 (en) 2012-06-21
RU2012104778A (en) 2013-08-20
HUE033888T2 (en) 2018-01-29
MX2020009978A (en) 2020-10-12
KR20120105417A (en) 2012-09-25
EP4141024A1 (en) 2023-03-01
US20220298496A1 (en) 2022-09-22
US20160097045A1 (en) 2016-04-07
US20150184141A1 (en) 2015-07-02
EP4299070A3 (en) 2024-03-27
JP2017070291A (en) 2017-04-13
CN106117325B (en) 2021-08-10
KR101667174B1 (en) 2016-10-17
CN106117325A (en) 2016-11-16
EP3252070A1 (en) 2017-12-06
HK1247629A1 (en) 2018-09-28
JP6704329B2 (en) 2020-06-03
AU2010273601A1 (en) 2012-02-02
CA2767760C (en) 2018-12-04
EP4299070A2 (en) 2024-01-03
JP2021193103A (en) 2021-12-23
US8129139B2 (en) 2012-03-06
US20120123095A1 (en) 2012-05-17
WO2011008713A1 (en) 2011-01-20
ES2643554T3 (en) 2017-11-23
US11203748B2 (en) 2021-12-21
JP2016028601A (en) 2016-03-03
KR101916139B1 (en) 2018-11-08
US8932827B2 (en) 2015-01-13
US8357541B2 (en) 2013-01-22
US11525130B2 (en) 2022-12-13
KR20190111161A (en) 2019-10-01
EP3252070B1 (en) 2019-10-02
US20220204958A1 (en) 2022-06-30
CA2767760A1 (en) 2011-01-20
US20230029327A1 (en) 2023-01-26
US20200071686A1 (en) 2020-03-05
ES2770031T3 (en) 2020-06-30
KR20180122039A (en) 2018-11-09
SI3252070T1 (en) 2020-03-31
US9719076B2 (en) 2017-08-01

Similar Documents

Publication Publication Date Title
MX375629B (en) PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN.
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
PH12014501039B1 (en) Cytotoxic peptides and antibody drug conjugates thereof
PH12015501846A1 (en) Novel antibody conjugates and uses thereof
MX365496B (en) Methods and systems for purifying non-complexed botulinum neurotoxin.
MX2009013194A (en) Page fusion proteins.
WO2011140135A3 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
EA201270722A1 (en) RIFAXIMINE FORMS AND THEIR APPLICATION
AR090973A1 (en) USEFUL ANTIBODIES FOR CANCER DIAGNOSIS
WO2012009289A3 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
EA201790309A1 (en) ANTIBODIES TO FAP, METHODS OF THEIR RECEPTION AND APPLICATION
EP4006030A3 (en) Methods and compositions for inhibiting the interaction of menin with mll proteins
AU2016264323A8 (en) Compositions and methods for TCR reprogramming using fusion proteins
PH12012502215A1 (en) Anti-fgfr2 antibodies
UA109278C2 (en) MEDICINES THAT CAUSE APOPTOSIS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES
MX2016003943A (en) Compositions and formulations for prevention and reduction of tumorigenesis, cancer cell proliferation and invasion, and methods of production and use thereof in cancer treatment.
WO2012149299A3 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP3060237A4 (en) Methods, systems and compositions relating to cell conversion via protein induced in-vivo cell reprogramming
WO2011140132A9 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
WO2011139986A3 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
WO2011143482A3 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
WO2011150279A3 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
NO20090305L (en) Cyclosporine formulations
EP4302783A3 (en) Modified relaxin polypeptides and their uses
EP2596122A4 (en) Modulators for sirt5 and assays for screening same